August 8, 2022

Medical Trend

Medical News and Medical Resources

New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients


New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients


 

New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients.

In a clinical trial, 80% patients with a specific type of lymphoma had their tumors shrunk after using Zanubrutinib.

Lymphoma cancer is one of the most common cancers in the United States, accounting for about 4 percent of all cancer cases.

Lymphoma cancer can occur at any age. In fact, it is one of the most common cancers in children, adolescents and young adults.

Still, the chance of getting lymphoma cancer increases with age, with more than half of patients 65 or older at the time of diagnosis.

 

New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients

 

 

 

 

Lymphoma is a cancer that involves the lymphatic system, which is an integral part of the body’s mechanism to fight germs.

There are many different types of lymphoma, but the two most common are Hodgkin lymphoma and non-Hodgkin lymphoma.

 

In an earlier study conducted at the University of Michigan Health’s Roger Cancer Center, the oral drug Zanubrutinib was shown to help most patients with a slow-growing type of cancer called marginal zone lymphoma.

 

Of the 20 patients with marginal zone lymphoma enrolled in the clinical study, 80 percent had their cancers shrunk, and one in five had complete remissions.

In 33 people with follicular lymphoma, a similar cancer, response rates to the drug were greatly reduced. 18% showed no signs of cancer when they had imaging tests.

 

The most common side effects of Zanubrutinib were diarrhea, bruising, and rashes, as well as colds, fever, and low levels of white blood cells, which are important for fighting infections and are part of the immune system.

 

New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients

Stained and magnified human lymphoma tumor cells. Source: National Cancer Institute/National Institutes of Health

 

Based on the results of this study and a secondary study codenamed MAGNOLIA, the U.S. Food and Drug Administration approved Zanubrutinib as an emergency treatment for adults with marginal zone lymphoma who have relapsed or have proven resistant to other treatments.

 

“Better tolerance and better disease control are greatly needed in marginal zone lymphoma and follicular lymphoma,” said Tycel Phillips, MD, a hematologist at Roger Cancer Center, clinical associate professor at the University of Michigan School of Medicine, and lead author of the study. Although the small size of this study limits broad conclusions, the safety and efficacy results highlight the potential of Zanubrutinib as a complement to existing therapies for these cancers.”

 

Lymphoma is a cancer that begins in the lymphatic system, the tissues and organs that produce and store white blood cells.

Marginal zone and follicular lymphomas develop when white blood cells called B cells become damaged and begin to grow uncontrollably.

 

So far, doctors have been unable to cure patients with marginal zone or follicular lymphoma with chemotherapy, so researchers have been eager to find other, more tolerable, successful treatments for the disease.

 

Zanubrutinib is a new class of drugs called Bruton’s tyrosine kinase inhibitors that block an enzyme called BTK that plays a key role in a signaling pathway that lymphomas often rely on, to survive and grow. The drug is the third BTK inhibitor approved to treat cancers that start in B cells.

 

 

 

New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients

(source:internet, reference only)


Disclaimer of medicaltrend.org